Clazakizumab - Vitaeris

Drug Profile

Clazakizumab - Vitaeris

Alternative Names: ALD 518; ALD518-003; BMS-645429; BMS-945429

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alder Biopharmaceuticals
  • Developer Alder Biopharmaceuticals; Vitaeris
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Inflammation; Psoriatic arthritis; Rheumatoid arthritis
  • Suspended Anaemia; Cachexia; Fatigue; Stomatitis
  • No development reported Crohn's disease; Graft-versus-host disease

Most Recent Events

  • 05 Dec 2017 Vitaeris enters into an agreement with CSL for development of clazakizumab for Transplant rejection
  • 29 Aug 2017 Clazakizumab is still at phase II development stage for Rheumatoid arthritis and Psoriatic arthritis in countries worldwide (SC)
  • 29 Aug 2017 Phase-II clinical trials in Inflammation (Chronic inflammatory diseases) in Canada (SC) (Alder BioPharmaceuticals pipeline, August 2017) (Vitaeris website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top